Stock Track | Neurocrine Biosciences Plummets 5.01% on Disappointing Q4 Earnings and Lackluster Outlook

Stock Track

Feb 11, 2025

Neurocrine Biosciences (NBIX) stock plummeted 5.01% in intraday trading on Monday, February 10th, 2025, as investors reacted to the company's lackluster fourth-quarter earnings and conservative outlook for the year.

Despite revenue increasing by 21.8% year-over-year to $627.7 million in Q4, NBIX's net income dropped 30% to $103.1 million from $147.7 million in the same period last year. For the full year 2024, revenue grew 24.8% to $2.355 billion, while net income rose 36.68% to $341.3 million.

However, the company's guidance for 2025 fell short of expectations, projecting full-year net product sales between $2.5 billion and $2.6 billion. Investors viewed this outlook as conservative, leading to the stock's sharp decline. NBIX's CEO Kyle Gano remained optimistic, stating, "With a rapidly advancing and growing pipeline and a strong financial profile, we are well positioned to build a leading neuroscience company."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1104172048"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104172048\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1104172048?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-11 01:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104172048","market":"us","top_or_hot":-1,"title":"Stock Track | Neurocrine Biosciences Plummets 5.01% on Disappointing Q4 Earnings and Lackluster Outlook","media":"Stock Track","content":"<p>Neurocrine Biosciences (NBIX) stock plummeted 5.01% in intraday trading on Monday, February 10th, 2025, as investors reacted to the company's lackluster fourth-quarter earnings and conservative outlook for the year.</p>\n\n<p>Despite revenue increasing by 21.8% year-over-year to $627.7 million in Q4, NBIX's net income dropped 30% to $103.1 million from $147.7 million in the same period last year. For the full year 2024, revenue grew 24.8% to $2.355 billion, while net income rose 36.68% to $341.3 million.</p>\n\n<p>However, the company's guidance for 2025 fell short of expectations, projecting full-year net product sales between $2.5 billion and $2.6 billion. Investors viewed this outlook as conservative, leading to the stock's sharp decline. NBIX's CEO Kyle Gano remained optimistic, stating, \"With a rapidly advancing and growing pipeline and a strong financial profile, we are well positioned to build a leading neuroscience company.\"</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Neurocrine Biosciences Plummets 5.01% on Disappointing Q4 Earnings and Lackluster Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Neurocrine Biosciences Plummets 5.01% on Disappointing Q4 Earnings and Lackluster Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-11 01:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Neurocrine Biosciences (NBIX) stock plummeted 5.01% in intraday trading on Monday, February 10th, 2025, as investors reacted to the company's lackluster fourth-quarter earnings and conservative outlook for the year.</p>\n\n<p>Despite revenue increasing by 21.8% year-over-year to $627.7 million in Q4, NBIX's net income dropped 30% to $103.1 million from $147.7 million in the same period last year. For the full year 2024, revenue grew 24.8% to $2.355 billion, while net income rose 36.68% to $341.3 million.</p>\n\n<p>However, the company's guidance for 2025 fell short of expectations, projecting full-year net product sales between $2.5 billion and $2.6 billion. Investors viewed this outlook as conservative, leading to the stock's sharp decline. NBIX's CEO Kyle Gano remained optimistic, stating, \"With a rapidly advancing and growing pipeline and a strong financial profile, we are well positioned to build a leading neuroscience company.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NBIX","symbol_name":"神经分泌生物科学","start_time":0,"source_url":"","article_id":"1104172048","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104172048","pubTimestamp":1739208409,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Neurocrine Biosciences  stock plummeted 5.01% in intraday trading on Monday, February 10th, 2025, as investors reacted to the company's lackluster fourth-quarter earnings and conservative outlook for the year.Despite revenue increasing by 21.8% year-over-year to $627.7 million in Q4, NBIX's net income dropped 30% to $103.1 million from $147.7 million in the same period last year. For the full year 2024, revenue grew 24.8% to $2.355 billion, while net income rose 36.68% to $341.3 million.However,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NBIX":"神经分泌生物科学"},"translate_title":"Neurocrine Biosciences因第四季度盈利令人失望和前景黯淡而暴跌5.01%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":1},"content_text":"Neurocrine Biosciences (NBIX) stock plummeted 5.01% in intraday trading on Monday, February 10th, 2025, as investors reacted to the company's lackluster fourth-quarter earnings and conservative outlook for the year.\nDespite revenue increasing by 21.8% year-over-year to $627.7 million in Q4, NBIX's net income dropped 30% to $103.1 million from $147.7 million in the same period last year. For the full year 2024, revenue grew 24.8% to $2.355 billion, while net income rose 36.68% to $341.3 million.\nHowever, the company's guidance for 2025 fell short of expectations, projecting full-year net product sales between $2.5 billion and $2.6 billion. Investors viewed this outlook as conservative, leading to the stock's sharp decline. NBIX's CEO Kyle Gano remained optimistic, stating, \"With a rapidly advancing and growing pipeline and a strong financial profile, we are well positioned to build a leading neuroscience company.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}